8-K: Aquestive Therapeutics Announces Positive Progress on Anaphylm and Libervant, Reports Q3 2024 Financial Results

Aquestive Therapeutics reported its third quarter 2024 financial results, highlighted by advancements in its Anaphylm and Libervant programs, and reaffirmed its cash runway into 2026.

Summary

• Aquestive Therapeutics reported a revenue increase to $13.5 million in Q3 2024, up from $13.0 million in Q3 2023, primarily driven by license and royalty revenue.
• The company's net loss for Q3 2024 was $11.5 million, or $0.13 per share, compared to a net loss of $2.0 million, or $0.03 per share, in Q3 2023.
• Research and development expenses increased to $5.3 million in Q3 2024, up from $3.2 million in Q3 2023, due to the advancement of the Anaphylm program.
• Selling, general, and administrative expenses rose to $12.1 million in Q3 2024 from $7.4 million in Q3 2023, partly due to increased commercial spending and regulatory fees.
• Non-GAAP adjusted EBITDA loss was $6.6 million in Q3 2024, compared to a loss of $1.3 million in Q3 2023.
• The company finished Q3 2024 with approximately $78 million in cash and cash equivalents.
• Aquestive reaffirmed its cash runway into 2026.
• The company expects full-year 2024 total revenue to be between $57 and $60 million and a non-GAAP adjusted EBITDA loss between $20 and $23 million.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there is positive progress in clinical trials and market access for key products, the increased net loss and EBITDA loss are concerning. The company's cash position and future outlook provide some optimism, but the financial results temper the overall sentiment.

Positives

• Anaphylm demonstrated rapid symptom resolution in the OASIS study, with a median time of 12 minutes.
• Anaphylm's PK profile remained consistent during allergen exposure.
• Libervant has achieved nationwide retail distribution and Medicaid reimbursement in all states for patients aged 2-5.
• The company has a strong cash position of approximately $78 million, extending its cash runway into 2026.
• AQST-108 showed no serious adverse events in its Phase 1 study.
• The company has secured agreements with 2 of the top 3 PBMs for Libervant patients aged 2-5.

Negatives

• The company's net loss increased significantly in Q3 2024 to $11.5 million, compared to $2.0 million in Q3 2023.
• Non-GAAP adjusted EBITDA loss was $6.6 million in Q3 2024, compared to a loss of $1.3 million in Q3 2023.
• Manufacture and supply revenue decreased to $10.7 million in Q3 2024 from $11.4 million in Q3 2023.
• Research and development expenses increased to $5.3 million in Q3 2024 from $3.2 million in Q3 2023.
• Selling, general and administrative expenses increased to $12.1 million in Q3 2024 from $7.4 million in Q3 2023.

Risks

• There are risks associated with the development and regulatory approval of Anaphylm, AQST-108, and Libervant, including potential delays or the need for additional clinical studies.
• The company faces the risk of not overcoming the orphan drug market exclusivity for Libervant for patients aged 6 and older until January 2027.
• There is a risk of a legal challenge to the U.S. market approval of Libervant for patients aged 2-5.
• The company faces risks related to commercializing new products, including market acceptance and competition.
• There are risks associated with the company's ability to secure sufficient capital and cash resources.
• The company faces risks related to manufacturing capabilities and the potential for eroding market share for Suboxone.
• There are risks related to intellectual property rights and potential infringement claims.

Future Outlook

Aquestive expects full-year 2024 total revenue to be between $57 and $60 million and a non-GAAP adjusted EBITDA loss between $20 and $23 million. The company anticipates initiating a full product launch of Anaphylm in the first quarter of 2026, if approved by the FDA. They also plan to commence a Phase 2a study for AQST-108 in the second quarter of 2025.

Management Comments

• Daniel Barber, President and Chief Executive Officer of Aquestive, stated that their innovative epinephrine prodrug platform remains the cornerstone of their development strategy.
• He also noted the significant milestone reached with the clinical development program for Anaphylm and the progress of AQST-108.
• Management highlighted the successful expansion of Libervant's market presence.

Industry Context

This announcement reflects the ongoing efforts in the pharmaceutical industry to develop innovative drug delivery methods, particularly for emergency treatments like anaphylaxis and seizure clusters. The focus on oral and topical delivery systems addresses the need for more convenient and patient-friendly alternatives to traditional injections and devices. The development of a topical treatment for alopecia areata also addresses a significant unmet need in dermatology.

Comparison to Industry Standards

• Aquestive's Anaphylm is positioned as a potential alternative to epinephrine autoinjectors like EpiPen, aiming for a more user-friendly oral delivery method. The median time to symptom resolution of 12 minutes is a key metric, which compares favorably to the time it takes for an injection to take effect.
• The development of AQST-108 as a topical treatment for alopecia areata is a novel approach, contrasting with existing systemic treatments like JAK inhibitors, which have known side effects and black box warnings. The estimated market opportunity for JAK inhibitors is over one billion dollars, indicating the potential for AQST-108.
• Libervant's approval for patients aged 2-5 addresses a specific need for a non-invasive treatment for seizure clusters, competing with existing rectal gel and nasal spray products. The company's focus on expanding market access and securing reimbursement is crucial for its commercial success.
• The company's manufacturing of 44 million doses in Q3 2024 demonstrates its ability to support its own products and its collaborations, which is comparable to other pharmaceutical companies with similar manufacturing capabilities.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and EBITDA loss, but encouraged by the progress of key product candidates.
• Employees may be impacted by the company's financial performance and the success of its product launches.
• Patients with severe allergies and epilepsy stand to benefit from the development of Anaphylm and Libervant.
• Customers and suppliers may be affected by the company's manufacturing and distribution activities.
• Creditors may be impacted by the company's financial performance and debt obligations.

Next Steps

• Aquestive will hold a pre-NDA meeting with the FDA for Anaphylm in Q4 2024.
• The company plans to commence a pediatric study for Anaphylm immediately following the pre-NDA meeting.
• Aquestive intends to complete the NDA submission for Anaphylm in Q1 2025.
• The company will hold a pre-IND meeting with the FDA for AQST-108 in Q4 2024.
• Aquestive plans to initiate a Phase 2a study for AQST-108 in Q2 2025.
• The company will continue to expand market access for Libervant for patients aged 2-5.
• Aquestive will continue to negotiate with commercial pharmacy benefit manager companies (PBMs).

Key Dates

Keywords

Anaphylm, Libervant, AQST-108, epinephrine, alopecia areata, seizure clusters, pharmaceuticals, FDA, clinical trials, sublingual film, topical gel, orphan drug exclusivity, revenue, EBITDA